Shingrix Dosage/Direction for Use

Posology: The primary vaccination schedule consists of two doses of 0.5 ml each: an initial dose followed by a second dose 2 months later.
If flexibility in the vaccination schedule is necessary, the second dose can be administered between 2 and 6 months after the first dose (see Pharmacology: Pharmacodynamics under Actions).
For subjects who are or might become immunodeficient or immunosuppressed due to disease or therapy, and whom would benefit from a shorter vaccination schedule, the second dose can be given 1 to 2 months after the initial dose (see Pharmacology: Pharmacodynamics under Actions).
The need for booster doses following the primary vaccination schedule has not been established (see Pharmacology: Pharmacodynamics under Actions).
Shingrix can be given with the same schedule in individuals previously vaccinated with live attenuated HZ vaccine (see Pharmacology: Pharmacodynamics under Actions).
Shingrix is not indicated for prevention of primary varicella infection (chickenpox).
Paediatric population: The safety and efficacy of Shingrix in children and adolescents have not been established. No data are available.
Method of administration: For intramuscular injection only, preferably in the deltoid muscle.
For instructions on reconstitution of the medicinal product before administration, see Special precautions for disposal and other handling under Cautions for Usage.